These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36945540)

  • 1. Direct prediction of Homologous Recombination Deficiency from routine histology in ten different tumor types with attention-based Multiple Instance Learning: a development and validation study.
    Loeffler CML; El Nahhas OSM; Muti HS; Seibel T; Cifci D; van Treeck M; Gustav M; Carrero ZI; Gaisa NT; Lehmann KV; Leary A; Selenica P; Reis-Filho JS; Bruechle NO; Kather JN
    medRxiv; 2023 Mar; ():. PubMed ID: 36945540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of homologous recombination deficiency from routine histology with attention-based multiple instance learning in nine different tumor types.
    Loeffler CML; El Nahhas OSM; Muti HS; Carrero ZI; Seibel T; van Treeck M; Cifci D; Gustav M; Bretz K; Gaisa NT; Lehmann KV; Leary A; Selenica P; Reis-Filho JS; Ortiz-Bruechle N; Kather JN
    BMC Biol; 2024 Oct; 22(1):225. PubMed ID: 39379982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.
    Cristescu R; Liu XQ; Arreaza G; Chen C; Albright A; Qiu P; Marton MJ
    BMC Cancer; 2022 Dec; 22(1):1310. PubMed ID: 36517748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors.
    Zhao D; Wang A; Li Y; Cai X; Zhao J; Zhang T; Zhao Y; Dong Y; Zhou F; Li Y; Wang J
    J Natl Cancer Cent; 2024 Sep; 4(3):280-287. PubMed ID: 39281716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homologous Recombination Deficiency Score Determined by Genomic Instability in a Romanian Cohort.
    Rădoi VE; Țurcan M; Maioru OV; Dan A; Bohîlțea LC; Dumitrescu EA; Gheorghe AS; Stănculeanu DL; Thodi G; Loukas YL; Săbău ID
    Diagnostics (Basel); 2023 May; 13(11):. PubMed ID: 37296748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation.
    Sahajpal NS; Mondal AK; Vashisht A; Singh H; Pang AWC; Saul D; Nivin O; Hilton B; DuPont BR; Kota V; Savage NM; Hastie AR; Chaubey A; Kolhe R
    Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.
    Kang J; Na K; Kang H; Cho U; Kwon SY; Hwang S; Lee A
    PLoS One; 2024; 19(3):e0298128. PubMed ID: 38527014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
    Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
    BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer.
    Wu X; Wang Q; Liu P; Sun L; Wang Y
    Front Genet; 2022; 13():1026871. PubMed ID: 36468004
    [No Abstract]   [Full Text] [Related]  

  • 11. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
    Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
    J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
    Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
    J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
    Watanabe T; Honda T; Totsuka H; Yoshida M; Tanioka M; Shiraishi K; Shimada Y; Arai E; Ushiama M; Tamura K; Yoshida T; Kanai Y; Kohno T
    Breast Cancer Res Treat; 2020 Jul; 182(2):491-502. PubMed ID: 32488393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
    Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
    Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response.
    Moore JA; Chen KT; Madison R; Newberg JY; Fleischmann Z; Wang S; Sharaf R; Murugesan K; Fendler BJ; Hughes J; Schrock AB; Hegde PS; Oxnard GR; Fabrizio D; Frampton GM; Antonarakis ES; Sokol ES; Jin DX
    JCO Precis Oncol; 2023 Sep; 7():e2300093. PubMed ID: 37769224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
    Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD).
    Rempel E; Kluck K; Beck S; Ourailidis I; Kazdal D; Neumann O; Volckmar AL; Kirchner M; Goldschmid H; Pfarr N; Weichert W; Hübschmann D; Fröhling S; Sutter C; Schaaf CP; Schirmacher P; Endris V; Stenzinger A; Budczies J
    NPJ Precis Oncol; 2022 Jun; 6(1):36. PubMed ID: 35681079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer.
    Long M; Liu H; Wu J; Wang S; Liao X; Liu Y; Hu T
    Comput Math Methods Med; 2022; 2022():5508301. PubMed ID: 35855837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    Miller RE; Leary A; Scott CL; Serra V; Lord CJ; Bowtell D; Chang DK; Garsed DW; Jonkers J; Ledermann JA; Nik-Zainal S; Ray-Coquard I; Shah SP; Matias-Guiu X; Swisher EM; Yates LR
    Ann Oncol; 2020 Dec; 31(12):1606-1622. PubMed ID: 33004253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.